视网醇结合蛋白4在心力衰竭中的潜在作用:一篇评论
Jiayi Liu1,2,3, Yaping Wang1,2,3
1Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 310009 Hangzhou, Zhejiang, China.
Reviews in cardiovascular medicine
|October 15, 2025
概括
视网醇结合蛋白4 (RBP4) 在心力衰竭 (HF) 患者中升高,与疾病严重程度有关. 本综述探讨了RBP4在HF病原发生中的作用及其作为诊断生物标志物的潜力.
科学领域:
- 心脏病学 心脏病学
- 生物化学 生物化学
- 内分泌学 在内分泌学.
背景情况:
- 心力衰竭 (HF) 是一个日益严重的全球健康问题,特别是在年轻人中,需要改进预测和预防策略.
- 视网醇结合蛋白4 (RBP4),一种由肝脏和脂肪组织分泌的蛋白质,越来越多地被认为与高血压相关.
- 血清RBP4水平升高与HF严重程度相关,包括纽约心脏协会 (NYHA) 类和左心室功能障碍.
研究的目的:
- 审查目前关于RBP4在心力衰竭进展中的病理生理学作用的临床和实验证据.
- 评估RBP4作为HF诊断生物标志物的潜力.
- 突出了对RBP4在HF中的机制进行进一步研究的需要.
主要方法:
- 关于RBP4和HF的临床研究和基础科学研究的综合文献综述.
- 分析现有数据,将血清RBP4水平与HF患者特征和结果联系起来.
- 对RBP4在心血管疾病中的分子机制的实验发现的综合.
主要成果:
- 在HF患者中持续观察到血清RBP4水平升高.
- RBP4与HF严重程度和左心室功能障碍指标的关联.
- 新出现的证据表明,RBP4与胰岛素耐药性,慢性炎症和直接心肌细胞损伤有关,有助于HF的发病.
结论:
- 在心力衰竭的发病和进展中,RBP4起着重要作用.
- RBP4显示出作为HF诊断生物标志物的潜力,尽管目前临床实用性有限.
- 进一步的临床和基础科学研究至关重要,以充分阐明RBP4在HF中的作用和治疗潜力.
更多相关视频
08:18Author Spotlight: Unraveling Vitamin A Transport Mechanisms — Linking Liver Receptors to Vision Health Through RBPR2 and RBP4 Interactions
Published on: October 4, 2024
1.5K
06:47A Pulmonary Trunk Banding Model of Pressure Overload Induced Right Ventricular Hypertrophy and Failure
Published on: November 29, 2018
10.1K
相关概念视频
01:17Pathophysiology of Heart Failure
2.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.9K
01:29Heart Failure II: Pathophysiology
722
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
722
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
453
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
453
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
538
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
538
01:30Heart Failure IV: Classification and Diagnostic Evaluation
319
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
319
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
932
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
932